Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GMAB Genmab A/S	$22.20 +1.8%	$20.14	$17.24 ▼ $28.56	$14.23B	0.96	1.16 million shs	956,446 shs
ITCI Intra-Cellular Therapies	$131.87	$131.87	$66.26 ▼ $131.98	$14.05B	0.69	1.56 million shs	N/A
KRYS Krystal Biotech	$136.94 +3.3%	$149.85	$122.80 ▼ $219.34	$3.96B	0.65	312,042 shs	265,790 shs
TEVA Teva Pharmaceutical Industries	$17.76 +3.0%	$15.72	$12.47 ▼ $22.80	$20.37B	0.6	10.17 million shs	11.57 million shs

20 High-Yield Dividend Stocks that Could Ruin Your Retirement

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GMAB Genmab A/S	0.00%	+6.07%	+14.49%	+1.00%	-20.06%
ITCI Intra-Cellular Therapies	0.00%	0.00%	0.00%	+0.47%	+92.76%
KRYS Krystal Biotech	0.00%	+7.78%	+3.56%	-25.47%	-16.71%
TEVA Teva Pharmaceutical Industries	0.00%	+5.90%	+4.84%	+20.94%	+5.59%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GMAB Genmab A/S	3.3659 of 5 stars	3.3	3.0	0.0	0.0	2.4	0.0	3.1
ITCI Intra-Cellular Therapies	0.884 of 5 stars	1.1	0.0	0.0	4.5	0.0	1.7	0.6
KRYS Krystal Biotech	4.4803 of 5 stars	3.5	1.0	0.0	4.7	2.1	3.3	1.9
TEVA Teva Pharmaceutical Industries	3.6798 of 5 stars	4.6	3.0	0.8	0.0	2.5	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GMAB Genmab A/S	2.69	Moderate Buy	$39.17	76.43% Upside
ITCI Intra-Cellular Therapies	2.17	Hold	$109.70	-16.81% Downside
KRYS Krystal Biotech	3.00	Buy	$211.13	54.17% Upside
TEVA Teva Pharmaceutical Industries	3.20	Buy	$24.44	37.64% Upside

Current Analyst Ratings Breakdown

Latest KRYS, TEVA, ITCI, and GMAB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/6/2025	TEVA Teva Pharmaceutical Industries	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$24.00
5/28/2025	TEVA Teva Pharmaceutical Industries	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$25.00
5/27/2025	TEVA Teva Pharmaceutical Industries	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/16/2025	KRYS Krystal Biotech	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$215.00 ➝ $155.00
5/12/2025	TEVA Teva Pharmaceutical Industries	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$21.00 ➝ $23.00
5/8/2025	TEVA Teva Pharmaceutical Industries	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $22.00
5/7/2025	KRYS Krystal Biotech	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$195.00 ➝ $189.00
5/7/2025	KRYS Krystal Biotech	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$219.00 ➝ $219.00
5/6/2025	KRYS Krystal Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$240.00 ➝ $240.00
4/28/2025	KRYS Krystal Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$221.00 ➝ $240.00
4/28/2025	TEVA Teva Pharmaceutical Industries	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 6/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GMAB Genmab A/S	$3.12B	4.57	$1.50 per share	14.80	$8.04 per share	2.76
ITCI Intra-Cellular Therapies	$680.50M	20.64	N/A	N/A	$6.15 per share	21.44
KRYS Krystal Biotech	$333.45M	11.87	$3.48 per share	39.38	$32.85 per share	4.17
TEVA Teva Pharmaceutical Industries	$16.62B	1.23	$3.52 per share	5.05	$4.75 per share	3.74

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GMAB Genmab A/S	$1.14B	$1.76	12.76	12.47	2.65	36.30%	16.78%	13.79%	8/14/2025 (Estimated)
ITCI Intra-Cellular Therapies	-$139.67M	-$0.73	N/A	694.05	N/A	-14.07%	-9.93%	-8.38%	N/A
KRYS Krystal Biotech	$10.93M	$4.16	45.80	13.59	N/A	30.69%	11.41%	10.40%	8/4/2025 (Estimated)
TEVA Teva Pharmaceutical Industries	-$1.64B	-$1.15	N/A	6.75	1.44	-9.91%	42.46%	6.65%	7/30/2025 (Estimated)

Latest KRYS, TEVA, ITCI, and GMAB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	GMAB Genmab A/S	$0.23	$0.31	+$0.08	$0.31	$5.17 billion	$715.00 million
5/7/2025	Q1 2025	TEVA Teva Pharmaceutical Industries	$0.47	$0.52	+$0.05	$0.18	$3.99 billion	$3.89 billion
5/6/2025	Q1 2025	KRYS Krystal Biotech	$1.38	$1.20	-$0.18	$1.20	$98.66 million	$88.18 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GMAB Genmab A/S	N/A	N/A	N/A	N/A	N/A
ITCI Intra-Cellular Therapies	N/A	N/A	N/A	N/A	N/A
KRYS Krystal Biotech	N/A	N/A	N/A	N/A	N/A
TEVA Teva Pharmaceutical Industries	$1.01	5.69%	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GMAB Genmab A/S	N/A	5.25	5.24
ITCI Intra-Cellular Therapies	N/A	7.66	7.51
KRYS Krystal Biotech	N/A	7.28	7.76
TEVA Teva Pharmaceutical Industries	2.97	0.98	0.75

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GMAB Genmab A/S	7.07%
ITCI Intra-Cellular Therapies	92.33%
KRYS Krystal Biotech	86.29%
TEVA Teva Pharmaceutical Industries	54.05%

Insider Ownership

Company	Insider Ownership
GMAB Genmab A/S	1.54%
ITCI Intra-Cellular Therapies	2.60%
KRYS Krystal Biotech	13.70%
TEVA Teva Pharmaceutical Industries	0.49%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GMAB Genmab A/S	1,660	641.20 million	651.58 million	Optionable
ITCI Intra-Cellular Therapies	560	106.52 million	103.56 million	Optionable
KRYS Krystal Biotech	210	28.90 million	24.71 million	Optionable
TEVA Teva Pharmaceutical Industries	36,800	1.15 billion	1.13 billion	Optionable

KRYS, TEVA, ITCI, and GMAB Headlines

Recent News About These Companies

The Goldman Sachs Group Begins Coverage on Teva Pharmaceutical Industries (NYSE:TEVA)

June 8 at 2:41 AM | americanbankingnews.com

Goldman Sachs Initiates Coverage of Teva Pharmaceutical Industries Limited - Depositary Receipt () (TEVA) with Buy Recommendation

June 7 at 7:00 AM | msn.com

Goldman Sachs Bullish On Branded Drug Upside At Teva: What About Viatris?

June 7 at 1:59 AM | benzinga.com

Traders Purchase High Volume of Teva Pharmaceutical Industries Call Options (NYSE:TEVA)

June 6 at 5:30 PM | marketbeat.com

The Goldman Sachs Group Initiates Coverage on Teva Pharmaceutical Industries (NYSE:TEVA)

June 6 at 9:29 AM | marketbeat.com

Teva Pharmaceutical Industries Limited (NYSE:TEVA) EVP Sells $105,626.12 in Stock

June 6 at 9:18 AM | insidertrades.com

Matthew Shields Sells 6,206 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) Stock

June 5, 2025 | marketbeat.com

Teva Pharmaceutical Industries Limited (TEVA) Presents at Jefferies Global Healthcare Conference Transcript

June 5, 2025 | seekingalpha.com

Teva Pharmaceutical prices and manages debt

June 4, 2025 | msn.com

Teva Announces Pricing and Early Acceptance Results of its Debt Tender Offer

June 3, 2025 | globenewswire.com

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Short Interest Update

June 3, 2025 | marketbeat.com

Teva Pharmaceutical Industries Ltd. Announces Early Tender Results and Increased Tender Caps for Note Offers

June 3, 2025 | quiverquant.com

Teva Announces Early Tender Results of its Debt Tender Offer, Increase to Tender Pool Caps and Total Maximum Amount and Election of Early Settlement

June 3, 2025 | globenewswire.com

Bourgeon Capital Management LLC Has $5.54 Million Stock Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

June 3, 2025 | marketbeat.com

Zacks Research Analysts Cut Earnings Estimates for TEVA

June 3, 2025 | americanbankingnews.com

Zacks Research Has Bearish Forecast for TEVA Q3 Earnings

June 2, 2025 | marketbeat.com

Teva Pharmaceutical Industries Ltd: New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025

June 1, 2025 | finanznachrichten.de

15,048 Shares in Teva Pharmaceutical Industries Limited (NYSE:TEVA) Purchased by Jefferies Financial Group Inc.

June 1, 2025 | marketbeat.com

New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care ...

May 31, 2025 | gurufocus.com

Teva Pharmaceutical Industries Limited (TEVA) Highlights Long-Acting Injectable Advancements for Schizophrenia at 2025 Psych Congress

May 31, 2025 | insidermonkey.com

Zacks Research Issues Positive Outlook for TEVA Earnings

May 31, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Defense Stocks That Will Profit From a Golden Dome
By Chris Markoch | May 30, 2025
View 3 Defense Stocks That Will Profit From a Golden Dome
Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
By Thomas Hughes | May 27, 2025
View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
Intel’s Turnaround May Be the Best Bet No One’s Watching
By Jeffrey Neal Johnson | May 30, 2025
View Intel’s Turnaround May Be the Best Bet No One’s Watching
Analysts Think These Stocks Could More Than Double in Value
By Nathan Reiff | May 23, 2025
View Analysts Think These Stocks Could More Than Double in Value
Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t Ignore
By Sam Quirke | May 14, 2025
View Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t Ignore

KRYS, TEVA, ITCI, and GMAB Company Descriptions

Genmab A/S NASDAQ:GMAB

$22.20 +0.39 (+1.79%)

Closing price 06/6/2025 04:00 PM Eastern

Extended Trading

$22.20 +0.00 (+0.02%)

As of 06/6/2025 04:04 PM Eastern

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Intra-Cellular Therapies NASDAQ:ITCI

$131.87 0.00 (0.00%)

As of 04/2/2025

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Krystal Biotech NASDAQ:KRYS

$136.94 +4.32 (+3.26%)

Closing price 06/6/2025 04:00 PM Eastern

Extended Trading

$136.47 -0.47 (-0.34%)

As of 06/6/2025 07:58 PM Eastern

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Teva Pharmaceutical Industries NYSE:TEVA

$17.76 +0.51 (+2.96%)

Closing price 06/6/2025 03:59 PM Eastern

Extended Trading

$17.65 -0.11 (-0.63%)

As of 06/6/2025 08:00 PM Eastern

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time